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Summary A rapid, functional and quantitative diagnostic method for the estimation of the P-glycoprotein (P-
gp)-dependent multidrug resistance is required in the clinical treatment of human tumours, as chemotherapy
protocols and resistance-reversing agents could be applied accordingly. In the present work, by using a calcein
accumulation method in combination with immunorecognition and drug-resistance studies, a new method is
described for the quantitative estimation of the expression and function of the multidrug transporter. MDR1-
transfected and drug-selected tumour cell lines with various levels of drug resistance were examined. The
expression of P-gp and its cell-surface appearance were assessed by quantitative immunoblotting and by
immunofluorescence cytometry. The transport function of the P-gp was assessed by measuring the extrusion of
calcein acetoxymethyl ester (AM) with fluorometry and flow cytometry, while in parallel experiments drug
resistance was directly examined in cell survival assays. The MDR1 activity factor (MAF), calculated from the
calcein AM extrusion assay, is demonstrated to provide a reliable quantitative measure for MDR1 specific
activity, reflecting cellular drug resistance. This relatively simple and rapid new functional P-gp assay surpasses
the formerly used techniques in both sensitivity and reproducibility.
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Ineffectiveness of tumour chemotherapy is often caused by
the resistance of malignant cells to a wide range of
hydrophobic cytostatic agents. The main characteristic of
these multidrug-resistant cells is an energy-dependent out-
ward transport of drugs by a membrane glycoprotein,
identified as P-gp [multidrug resistance protein (MDRl),
multidrug transporter]. Another key feature of multidrug
resistance is its potential reversibility by a great variety of
agents, such as verapamil, quinidine, calmodulin inhibitors,
phenothiazines, reserpine or cyclosporin A (Gottesman and
Pastan, 1993).
Reliable estimation of the level of multidrug resistance in
tumour cells would be extremely important in the clinical
treatment of various cancerous diseases, as combination
chemotherapy treatment protocols could be adjusted and
drug-resistance reversing agents could be applied accordingly.
However, current laboratory methods are mostly restricted to
the estimation of expression and/or surface appearance of
P-gp and are less suitable for a parallel and quantitative
estimation of the expression and function of this drug
transporter.
The P-gp function can be followed by measuring the
cellular uptake, efflux or steady-state distribution of several
fluorescent MDR1 substrates, e.g. anthracyclines (Herweijer
et al., 1989), verapamil derivatives (Lelong et al., 1991),
rhodamine 123 (Neyfakh, 1988; Chaudhary and Roninson,
1991); and Fluo-3 (Wall et al., 1991, 1993), SY-38 and SY-
3150 (Frey et al., 1995) respectively. However, these
fluorescence assays have serious drawbacks in quantifica-
tion. The fluorescence and the cellular distribution of these
compounds are dependent on pH, and the alteration of
intracellular pH depending on MDR1 expression has been
reported (Thiebaut et al., 1990; Roepe, 1992; Roepe et al.,
1993). In the case of Fluo-3, changes in intracellular free
calcium significantly alter the fluorescence of this calcium
indicator dye.
Fluorescence drug uptake measurements require relatively
long incubation periods (30-60 min) to achieve a clearly
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detectable (e.g. 4-fold) difference between the fluorescence in
drug-resistant and -sensitive cells (Herweijer et al., 1989). The
fluorescence of anthracyclines is quenched upon binding to
DNA and/or cellular components (Roepe, 1992; Goldstein et
al., 1992), therefore the determination of their intracellular
concentrations is uncertain. In addition, the initial anthracy-
cline efflux rate (Roepe, 1992), as well as the fast component
of the efflux rate of coumarin-conjugated vinblastine
(Bornmann and Roepe, 1994) was found to be independent
from the amount of expressed MDR1 over a wide range of
drug concentrations. A more accurate determination of
MDR1 activity can be achieved by using a flow-through
system, although a sophisticated kinetic analysis is required
for quantitative evaluation (Spolestra et al., 1992).
The fluorescence assay method most commonly used to
discriminate between drug-resistant and -sensitive cells is
based on the efflux of rhodamine 123, and a correlation of
MDR1-mediated rhodamine 123 efflux with mdrl mRNA
levels has been reported (Lee et al., 1994). Although the
sensitivity of this method is higher than that of the
fluorescent anthracycline measurements, the proper quantifi-
cation of the transport activity is hindered by a non-MDR1-
mediated efflux and by non-specific changes in rhodamine 123
fluorescence. This dye exhibits relatively poor cellular
retention, which strongly depends on the cell type, and
interacts with various intracellular compartments and
organelles (e.g. mitochondria), producing a spectral shift
and a change in fluorescence intensity (Weaver et al., 1991).
In addition, the rhodamine 123 efflux measurement raises
several technical problems: (i) initial dye concentrations are
diverse in different cell types (Lee et al., 1994); (ii) the
concentration of the transported substance changes during
the measurement. The determination of the efflux rate
constants from an exponential fluorescence decay may
overcome these problems, but at high loading levels-when
the transporter tends to be saturated with the dye-no
exponential decay was found (Altenberg et al., 1994). It has
also to be noted that for rhodamine efflux measurements cells
have to be incubated for 1-2 h (Lee et al., 1994; Mechetner
and Roninson, 1992), or even 3-10 h in clinical samples
(Chaudhary and Roninson, 1991) in a dye free medium after
a usual 30 min loading procedure.
We have formerly demonstrated that the hydrophobic
acetoxymethyl ester (AM) derivatives of various fluorescentQuantitative multidrug resistance assay
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indicators (Fura-2, Fluo-3, Indo-1, BCECF, calcein) are
actively extruded from cells by the multidrug transporter
(Homolya et al., 1993). Calcein AM (but not free calcein) is
an excellent activator of the MDR1 -ATPase in isolated
insect cell membranes (Ka, 1/IM) (Homolya et al., 1993), and
calcein accumulation is prevented in mouse fibroblasts
transfected with human MDR1 (Hollo et al., 1994). On the
basis of these findings we have suggested a calcein assay to
discriminate between drug-resistant and drug-sensitive cells.
Calcein AM, a non-fluorescent hydrophobic molecule,
rapidly penetrates cell membranes and becomes trapped
intracellularly upon conversion into fluorescent calcein (free
acid) by non-specific cytoplasmic esterases. Owing to the
continuous gradient of the AM compound, in a few minutes
of incubation the intracellular free dye concentrations can
increase to 100 to 500-fold of that of the calcein AM in the
medium. In the MDR1-expressing cells calcein AM is
extruded by the multidrug transporter before its intracellular
conversion to the non-MDR1 substrate-free calcein (Homo-
lya et al., 1993; Hollo et al., 1994). However, when this
calcein AM extrusion is blocked by an agent that interferes
with the MDR1 pump activity (e.g. verapamil), fluorescent-
free calcein rapidly accumulates.
This assay possesses numerous advantages over the
methods formerly used for the determination of MDR1
function. An efficient differentiation between drug-sensitive
and -resistant cells can be performed within 10- 15 min.
Calcein has a bright fluorescence that is practically insensitive
to pH, or to Ca2" and Mg2" concentrations, and does not
show spectral changes upon accumulation in intracellular
compartments or binding to cellular components (Haughland
and Larison, 1992). The most favourable property of this
assay method, based on AM extrusion, is that the detected
compound is different from the transported one. Thus, a
steady-state level of the MDR1-transported substrate is
detected by a coupled enzymatic reaction (i.e. esterase
cleavage). Owing to enzymatic enhancement of the dye-
trapping process, the sensitivity of this assay highly surpasses
that of the formerly used methods. The Fluo-3 accumulation
provided a 7-fold higher signal than doxorubicin accumula-
tion measurements (Wall et al., 1991). Owing to the higher
affinity of calcein AM to MDR1, as compared with that of
Fluo-3 AM (Homolya et al., 1993), the sensitivity of the
calcein assay is even higher (2.5-fold) than that of the Fluo-3
accumulation method, while avoiding the possible effects of
changes in cellular free calcium.
In the present paper we describe the parallel measurements
ofseveral morphological and functional characteristics of P-
gp in various multidrug-resistant human and mouse cell lines,
and provide an approach for the quantitative estimation ofthe
expression and function of this drug extrusion protein.
Materials and methods
Cell culturing
NIH 3T3 murine fibroblast cell line, its human MDR1-
transfected counterpart (NIH 3T3 MDR1 G185; Bruggemann
et al., 1992) and human epidermoid carcinoma (KB3 and KB-
VI) cell lines were obtained from Dr M M Gottesman
(National Institute of Cancer/National Institute of Health,
Bethesda, MD, USA). P388 murine leukaemia, F4-6 Friend
murine erythroleukaemia, K562 human erythroleukaemia cells
were obtained from Dr A Schaefer (Hamburg University
Medical School, Hamburg, Germany). NIH 3T3 cells and KB
cell lines were cultured in Dulbecco's modified Eagle medium
(DMEM) under standard conditions, while other cells were
grown in RPMI media. Culturing media were obtained from
Gibco/Life Technologies (Gaithersburg, MD, USA), and
supplemented with 10% fetal bovine serum (Sebak, Aiden-
bach, Germany), 5 mM glutamine, 100 units ml-' penicillin
and 100 pg ml-' streptomycin (Sigma Chemical , St. Louis,
MO, USA). Drug-selected cell lines were reselected by
culturing for 3 days in standard media containing cytostatic
agents. P388 and K562 cells were grown in media containing
50 ng ml-' and 100 ng ml-' doxorubicin (Sigma) respectively.
KB-V1 cells were cultured in media containing 500 ng ml-'
vincristine (Eli Lilly, Indianapolis, IN, USA). In order to
achieve different levels of drug resistance the selection
procedure was repeated several times.
Recombinant baculovirus carrying the human MDR1 gene
was generated, and the Sf9 (Spodopterafrugiperda) cells were
infected by the MDR1 baculovirus and cultured according to
the procedures described previously (Germann et al., 1990).
Separation ofmononuclear cells of leukaemia patients
Freshly drawn peripheral blood of leukaemia patients was
diluted with an equal volume of HPMI medium (Homolya et
al., 1993) and overlaid on Ficoll-Histopaque-1077 (Sigma).
The suspension was centrifuged at 1500 g for 15 min at room
temperature, the mononuclear cell-containing interface was
transferred to another tube, diluted with excess HPMI
medium, washed twice and finally resuspended in HPMI
medium.
Quantitative immunoblotting
Electrophoresis and immunoblotting with the 4077 polyclonal
antibody, which recognises both mouse and human MDR1
(Tanaka et al., 1990), were carried out as described in
Sarkadi et al. (1992). The second antibody was an anti-rabbit,
horse radish peroxidase (HRP)-conjugated goat IgG (Jackson
Immunoresearch, West Grove, PA, USA), used in
20 000 x dilution. HRP-dependent luminescence on the
polyvinyl difluoride (PVDF) membrane immunoblots (ECL
supplied by Amersham, Braunschweig, Germany) was
determined by excising the respective bands from the PVDF
membrane and measuring their luminescence in a liquid
scintillation counter (Beckman LS 6000, Single Photon
Monitor mode). The amounts of the expressed MDR1 were
calculated from the luminescence values, based on a
calibration by a dilution series of standard Sf9-MDRl
membrane preparations. By using this method a wide range
of luminescence intensities (over three orders of magnitude)
could be detected with high accuracy.
Fluorometry
Calcein accumulation was measured by incubating 2.5 x 105
cells ml-' in HPMI medium containing 0.25 gM calcein AM
(Molecular Probes, Eugene, OR, USA). Fluorescence was
measured at 37°C with gentle stirring in a Hitachi F-4000
fluorescence spectrophototmeter (excitation and emission
wavelengths for calcein were 493 and 515 nm respectively,
with a band width of 5 nm). Calibration ofdye concentration
was based on the measurement of free calcein fluorescence in
the same instrument under identical conditions. All experi-
ments were repeated at least three times with each batch of
cell preparations.
Flow cytometry
For immunofluorescence staining 8 x 105 cells were incubated
in HPMI medium containing 1% bovine serum albumin
(BSA) (Sigma) with the monoclonal antibody, UIC2
(10 ig ml-1), which reacts with extracellular epitope(s) of
the MDR1 protein (Mechetner and Roninson, 1992).
Labelling was performed at 4°C for 45 min, and the cells
were then washed twice with HPMI containing 1% BSA, and
once with HPMI. Thereafter 17 ,ug ml-' anti-mouse-FITC
antibody conjugate (Dako, Glostrup, Denmark) was applied,
similarly to the first antibody. Finally the cells were
resuspended in HPMI. Cellular fluorescence was measured
with a Cytoronabsolute (Ortho, Ortho Diagnostics Systems,
NJ, USA) flow cytometer.
For flow cytometry measurements of calcein uptake,
2 x 105 cells ml-' were preincubated with 100 gM verapamil
or with solvent dimethyl sulphoxide (DMSO) for 5 min at
25°C before the dye loading procedure. Thereafter 0.25,MQuantitative multidrug resistance assay
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calcein AM (final concentration in the HPMI medium) was
added and the cells were incubated for 10 min at 370C. Non-
living cells were detected and gated out by propidium iodide
staining. Data were analysed by the Winlist software (Verity
Software House, Topsham, ME, USA).
Drug resistance
Drug resistance of the various control and MDRl-containing
cell types was determined by cell counting after a 72 h
incubation of the cells in 24-well plates in the respective
culture media, supplemented with various concentrations of
the cytostatic agents.
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Results and discussion
The major aim of the present work was to establish a
correlation between the expression level of the MDR1 protein
and its functional consequence, the resistance to cytotoxic
agents in a wide variety of cell types. Therefore we followed
in parallel experiments P-gp expression, drug resistance and
dye pumping activity in several tumour cell lines. Human
epidermoid carcinoma (KB) and erythroleukaemia (K562), as
well as murine P388 leukaemia and Friend erythroleukaemia
(F4-6) cells were examined. All these cell lines had parent,
non-resistant (control) and multidrug-resistant (MDR)
counterparts, the latter with a great variety of drug
resistance, achieved by continuous drug selection. Since
MDR1 expression was variable in these cell lines, all parallel
determinations of P-gp expression and function were carried
out in samples obtained from the same cell batches. As a
reference, we used NIH 3T3 mouse fibroblasts and cells from
the same line stably transfected with human MDR1 cDNA
via a retroviral vector (Bruggemann et al., 1992). For the
quantitative estimation of the MDR1 protein on the
immunoblots, we used the insect (Sf9) cell expression system
(Germann et al., 1990).
Figure la represents Western blot detection of the P-gp in
protein extracts of human epidermoid carcinoma (KB) cell
lines with increasing levels of drug resistance. Figure lb
shows the immunoblot detection of P-gp in control and
MDRl-transfected NIH 3T3 cells, in control and doxorubicin
selected P388 mouse leukaemia cells, and in human MDRl-
expressing Sf9 cell membranes. In these experiments we used
a previously established method to ensure a full electroblot-
ting transfer of the large, heavily glycosylated MDR protein
to PVDF membranes (Sarkadi et al., 1992), and applied an
anti-human MDR1 polyclonal antibody (4077) that recog-
nises mouse MDR1 but does not show cross-reaction with
MDR2 (Tanaka et al., 1990), or, as demonstrated on Figure
1, with any other cellular protein.
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Figure 1 Quantitative detection of MDR1 expression by Western
blotting in various cell lines by the polyclonal antibody, 4077.
Increasing levels of P-gp expression have been detected (a) in a
series of human epidermoid carcinoma cell lines (KB3 non-
resistant; KB-Vla drug-resistant cells; KB-Vlbc generated by
further cytostatic drug selections from KB-Vla). (b) demonstrates
MDRl expression in NIH 3T3 control cells, MDRl-transfected
NIH 3T3 G185 cell line; as well as increasingly drug-resistant
murine leukaemia cell line (P388 C: non-resistant, MDRa: less
resistant, MDRb: highly resistant). As reference for quantitative
estimation of P-gp expression, Sf9 cells expressing human MDR1
were used. Both panels represent luminograms of the peroxidase-
stained blots, where each lane contained 20,uig of cellular protein,
except the last lane on (b), which contained 2yg of protein of Sf9
cell membranes. The numbers below the lanes represent the
determined P-gp amounts in jig MDR1 mg-' cellular protein
units. The IC50 values obtained for these cell types with
doxorubicin in a 3 day growth test were as follows:
KB3,<2nM; KB-Vla, 20nM; KB-Vlb, 60nM; KB-Vlc, 100nM;
NIH 3T3, 5nM; NIH 3T3 G185, 200nM; P388C,<1nM; P388-
MDRa, 4nM; P388-MDRb, 9nM.
Figure 2 Fluorometric time course of calcein accumulation in
drug-sensitive (P388-C) and increasingly drug-resistant (P388-
MDRa-b) cells. The cells were incubated in the presence of
0.25pM calcein AM and fluorescence was followed by spectro-
fluorometry. After 5min of incubation, a multidrug resistance
reversing agent, verapamil (100yM) was added to the medium.
Data of a representative experiment are plotted as fluorescence (in
arbitrary units) against time.
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The immunoreactive bands in Figure 1 represent the
MDRl protein, its glycosylated form running at an apparent
Mr of about 170 kDa, except the underglycosylated form
expressed in Sf9 cells, with an Mr of about 130 kDa. Based
on the quantitative luminescence measurements and the
known amount of MDRl protein in the isolated Sf9 cell
membranes (Sarkadi et al., 1992), MDR1 expression levels in
the different cell lines could be determined. The mean values
obtained in at least three different measurements for the
various cell lines are presented under the respective lanes. In
the case of mouse MDR1 antibody detection may be less
efficient, thus an underestimation of the amount of MDR1
may occur. However, the validity of these measurements is
supported by the finding that another polyclonal anti-human
MDR1 antibody (4007, prepared against the C-terminal
cytoplasmic domain; Tanaka et al., 1990) provided a similar
value for MDRl expression in all cell types examined (data
not shown).
The function of the multidrug transporter in these cell
lines was studied by using the calcein assay (Hollo et al.,
1994), combined with direct cell-survival studies. As
previously demonstrated, calcein trapping is slower in the
MDR1 expressing cells, owing to the extrusion ofcalcein AM
by the multidrug transporter. When calcein AM extrusion is
blocked by an agent that interferes with MDR1 (e.g.
verapamil), free calcein rapidly accumulates. As shown in
Figure 2 in a representative experiment, the decrease in dye
accumulation rate correlates with the level of MDR1
expression. In the control P388 murine leukaemia cells, in
the presence of 0.25 gM calcein AM, calcein accumulation is
rapid and the addition of 100 uM verapamil has practically
no effect either on calcein fluorescence or on its accumulation
rate. In contrast, in the MDRl-expressing P388a cells, calcein
accumulation is slower, and verapamil restores the dye
uptake rate to that found in control cells, showing that the
decreased dye accumulation is due to the MDR1 function.
This difference is even larger in the excessively drug-selected
P388b cells, in good correlation with the amount of the
expressed MDR1 protein (see Figure lb).
As shown in Figure 2, the slopes of fluorometric curves
are identical after the addition of verapamil, suggesting that
the reversal of reduced calcein accumulation was complete
and the applied concentration of verapamil did not modify
the cellular esterase activity. Although the affinity of calcein
AM to P-gp is higher than that of verapamil, a 10-fold
excess of the reversing agent was sufficient for complete
blocking of calcein AM extrusion (see Homolya et al., 1993).
In order to ensure a quantitative evaluation, the highest
concentration of verapamil (but still without non-specific
effect on the membrane permeability and/or cellular esterase
activity) was applied in these and the following experiments
and we found that calcein accumulation in the various
control cell lines was not affected by verapamil up to a
concentration of 150 gM.
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Figure 3 Flow cytometry detection ofcell-surface expression of MDR I (a) and calcein accumulation (b) in drug sensitive KB3, and
increasingly drug resistant KB-Vlac cell lines. The cells were labelled (a) with a human MDRI-specific monoclonal antibody,
UIC2, thereafter a FITC-conjugated anti-mouse second antibody was applied. Cellular green fluorescence intensity was determined
by flow cytometry. Representative data are shown as cell numbers plotted against log green fluorescence. Filled histograms show the
UIC2 labelled cells, while the isotype controls for each cell line are indicated as outlines. The cells from the same lines were loaded
(b) with 0.25 gM calcein in the absence * or presence C1 of 100 gM verapamil. The verapamil-treated cells are shown as an outline
on the histogram. Increasing level of MDR1 expression caused decreasing level ofcalcein accumulation in the absence ofverapamil,
while verapamil restored dye accumulation up to the control level.
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When cell survival was measured in media containing
different concentrations of doxorubicin, the IC50 values for
the above-presented three P388 cell lines were 0.7, 3.7 and
9.0 ng doxorubicin ml-' respectively. These resistance factors
were in good correlation with the results obtained from the
fluorometric curves shown in Figure 2. A similar close
correlation between MDRl expression, drug resistance and
calcein accumulation was observed in several other cell lines
(see the legend to Figure 1 and below).
Since the plasma membrane insertion of the MDRl is
required for its drug-extrusion activity, in parallel flow
cytometry measurements we have determined the cell-surface
expression and the pumping activity of P-gp. For immuno-
fluorescence labelling the UIC2 monoclonal antibody was
applied, which reacts exclusively with extracellular epitope(s)
of human P-gp (Mechetner and Roninson, 1992). As
demonstrated in Figure 3a, the cell surface labelling by
UIC2 is in accordance with the immunoblot data (see Figure
la). The immunofluorescence labelling was compared with
the labelling with an IgG, isotype control, indicated as an
outline. In similar experiments the MDR1 cell-surface
expression was determined in several cell lines expressing
human P-gp (see below), and a linear correlation was found
between UIC2 binding and MDR1 levels measured by
quantitative immunoblotting (r =0.970, P = 1.6 x 10 7).
Figure 3b demonstrates the flow cytometry measurements
of calcein accumulation in the same series of KB cells as
shown in Figure 3a. The cells were incubated for 10 min with
calcein AM in the absence and presence of verapamil
respectively. As demonstrated, calcein accumulation showed
a mirror image of the cell-surface labelling by UIC2, that is
the more P-gp was expressed, the lower level of calcein
fluorescence was detected. Verapamil restored calcein
accumulation to the control level. The sensitivity of the
assay in most cases remarkably surpassed that of the cell
surface labelling, but both measurements reflected the relative
doxorubicin resistance in these different MDR1-expressing
KB cells (see the legend to Figure 1).
Since the decrease in dye uptake rate correlates both with
MDR1 expression and drug resistance, the calcein assay may
provide an opportunity for quantitative determination of the
MDR1 function. If dye extrusion is entirely blocked by
verapamil, the difference between the dye uptake rates after
and before verapamil addition respectively, reflects the
pumping activity of the multidrug transporter. In order to
eliminate the errors arising from differences in esterase
activity, cell volume and other fluctuations in the experi-
mental conditions (e.g. cell number, dye concentration,
parameters of the fluorescence equipment, etc.), the
difference was normalised to an internal standard, provided
by the dye uptake rate after the addition of verapamil. Thus,
MDR1 activity was expressed by the following dimensionless
empirical paramater:
MDR1 activity factor: MAF = (F* -F)/F* (1)
where F* and F designate the dye accumulation rates in the
presence and absence of an MDR1 inhibitor respectively. We
have examined the appropriate conditions for calcein assay in
great detail, and found that at pH values in the media
between 7.0 and 7.8, at calcein AM concentrations between
0.1 and 1 gM and at cell numbers between 5 x 104 ml-' and
2 x 106 ml-, the value of the MDR1 activity factor remained
practically unchanged. Free calcein leakage was found to be
extremely slow, its half-time being over 5 h at 25 and 37°C,
both in the control and the MDRl-expressing cells. We have
also examined the effects of various inhibitors of MDR1 (e.g.
vinblastine, vanadate, cyclosporin A) for calcein accumula-
tion (see Hollo et al., 1994), and found that whenever
maximum inhibition was achieved, the nature of inhibition
(competitive or non-competitive) did not influence the
obtained MAF value. In addition to the complete blocking
of calcein AM extrusion, the important features of the
MDR1 inhibitor applied in this test should be, that in the
concentrations used:
(i) it should not interfere with the fluorescence of
calcein;
(ii) it should not inhibit cellular esterase activity;
(iii) it should not change the non-specific membrane
permeability for calcein.
Figure 4a demonstrates in various cell types the
correlation between the MAF values calculated from the
fluorometric measurements (see Figure 2) and the levels of
MDR1 expression determined by quantitative immunoblot-
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Figure 4 Comparison of MDRl expression and function in
various cell types. Control cell lines: P388 C(z), K562 C (V),
KB3 (A), 3T3 C (0); drug-resistant counterparts with different
levels of MDR1 expression: P388 MDRa-b (U), K562 MDRa-b
(V), KB-Vla-. (A), F4-6 (*), 3T3 MDR1 (0). (a) MDR1
expression was quantitatively assessed by Western blotting by
using the 4077 polyclonal antibody and the HRP/ECL
luminescence method. The MDR1 activity factor (MAF) was
calculated for each cell line by using the calcein accumulation
rates determined before and after verapamil addition from the
fluorometric time courses, as shown in Figure 2, and by using
equation (1). The MDR1 activity factor (MAF)±+s.d. is plotted
against MDR1 contents+s.d. (in Mg MDR1 mg- cellular protein
units). The insert shows the enlarged initial part of the same
chart. (b) MDR1 expression was assayed by flow cytometry with
UIC2 antibody, and MDR1 activity factor (MAF) was
determined by flow cytometry calcein assay, as shown in Figure
3. The MAF values were calculated from the absolute
fluorescence obtained in the absence and presence of verapamil,
and by using equation (1). The MDR1 activity factor
(MAF)±s.d. is plotted against UIC2 labelling±s.d. (expressed
as the ratio of absolute fluorescence obtained with UIC2 and
isotype control immunolabelling respectively). Since MDR1
expression was transient in the drug-selected cell lines, samples
for immunodetection and functional assays were obtained from
the same cell batches, on the same day. All data points represent
at least three independent determinations. For the corresponding
IC50 values obtained for the different cell types with doxorubicin
in a 3 day growth test, see the legend to Figure 1. In the case of
the cells previously not shown, the ranges of these IC50 values
were as follows: K562C, <1 nM; K562 MDRa-b,5-50nM; F4-6
MDR, 80-120nM.
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ting (see Figure 1), while Figure 4b shows the MAF values
obtained in flow cytometry studies, correlated with the
MDR1 cell-surface expression determined by UIC2 labelling
(in this case only human MDRl is detected). For the
estimation of the MDRl activity (MAF) factor from the flow
cytometry data, the absolute fluorescence values were
calculated from the mean channel values, and inserted into
equation (1). Although in this case the MAF parameter was
calculated from mean values of 10 min accumulation rates,
the results were identical to those obtained from cell
population measurements in a spectrofluorimeter.
As shown in these studies, at low MDR1 expression levels
the value of MAF (providing an estimate of the pumping
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Figure 5 UIC2/FITC labelling and calcein accumulation proper-
ties of leucocytes of a patient suffering from chronic lymphocytic
leukaemia. Ficoll-separated leucocytes were labelled by the UIC2
monoclonal antibody, while another portion of the sample was
examined by the calcein accumulation assay. The FITC surface
labelling and the cellular calcein fluorescence were detected by
flow cytometry. (a) UIC2/FITC antibody labelling of the
leukaemic cells of a chronic lymphocytic leukaemia (CLL)
patient (dark grey histogram); the light-grey histogram shows
the labelling by the isotype control/FITC antibodies. Histograms
are depicted as an overlay. (b) The cells from the same clinical
sample were loaded with 0.25yM calcein in the absence or
presence of 100pM verapamil. The verapamil-pretreated cells are
shown in dark grey, whereas the cellular fluorescence of the cells
pretreated only with solvent, is shown by the light-grey histogram.
activity) is proportional to the level of protein expression,
whereas at high MDR1 levels MAF converges to 1 by nature.
Thus the sensitivity of this MDR1 activity factor is the
highest at lower MDR1 expression levels, correlating with a
lower relative resistance to doxorubicin (see the legends to
Figures 1 and 4). In all the cell lines examined here it has
been previously demonstrated in detail that the expression
levels of the MDR1 protein closely correlated with the
cellular resistance to a wide variety of various hydrophobic
drugs (Bruggemann et al., 1992). Since calcein AM is a high-
affinity substrate of the MDR1 transporter (Homolya et al.,
1993), the calcein accumulation assay is suggested to provide
an overall reflection of the cellular multidrug resistance.
The data presented here clearly demonstrate that the level
of P-gp expression in most cases shows a good correlation
with its function. However, the occurrence of a non-
functional P-gp may be misleading for conclusions related
to multidrug resistance in a given cell type, and only a
functional test may help in obtaining such a clinically
relevant laboratory diagnosis. In fact, in a K562 cell line
(generated in our laboratory), the expression of a non-
functional mutant of P-gp can be detected by immunoblot-
ting and UIC2 flow cytometry, but does not exhibit calcein
AM extrusion (data not shown). Another possibility, leading
to a positive calcein accumulation-derived MAF value
without MDR1 expression is the appearance of MRP
(multidrug-resistance associated protein; Cole et al., 1992),
which has recently been reported to extrude calcein from
tumour cells (Feller et al., 1995a b; Twentyman, personal
communication). In this latter case the specific antibody
labelling and the selective inhibition of the MDR- and/or
MRP-dependent calcein transport should help the proper
diagnosis (see Feller et al., 1995b).
The major goal of the above-described work has been to
introduce a quantitative assay panel for the rapid and simple
in vitro assessment of multidrug resistance in cells obtained
from patients suffering from cancer. Representative measure-
ments with lymphocytes of a patient with chronic
lymphocytic leukaemia are shown in Figure 5. The cell-
surface expression of P-gp was detected by UIC2 (Figure 5a),
indicating a 1.15 times increase in labelling, as compared with
the isotype control. In a parallel experiment the calcein
accumulation assay in the same sample (Figure 5b) showed a
clear measurable difference in the absence and presence of
verapamil respectively, yielding a MAF of 0.31. According to
our preliminary data obtained with leucocyte samples of
haematological patients, the clinically drug-resistant cells
show relatively low MDR1 expression, and are in the
MAF =0.05-0.5 range. As indicated by Figure 4, this is
the range where the MAF is proportional to P-gp expression
and the sensitivity of the method is the highest.
The above detailed analysis of multidrug resistance in
various cell lines suggests that a combination of cell-surface
MDR1 expression analysis, e.g. with monoclonal antibody
UIC2, and a quantitative functional test, e.g. by the calcein
accumulation assay with the calculation of MAF described
here, provides a safe way of quantitatively assessing the level
of multidrug resistance in clinical samples. In addition, the
favourable optical properties of calcein allow dual fluores-
cence studies to be performed, in which the functional assay
is carried out in surface marker-selected leukaemic (or other
tumour) cells. The unique restriction for such studies is that
the excitation and/or emission wavelengths of the fluorophore
of the tumour marker has to be remarkably dissimilar to that
of calcein (FITC and R-phycoerythrine conjugates are
incompatible). A detailed clinical study of multidrug
resistance in isolated leucocytes of haematological patients,
by using the above described assays, is underway in our
Institute.
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